Travere Therapeutics (TVTX) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TVTX shares.
View TVTX analyst ratings or view top-rated stocks.

11 analysts have issued twelve-month price objectives for Travere Therapeutics' stock. Their TVTX share price forecasts range from $17.00 to $42.00. On average, they expect the company's stock price to reach $30.85 in the next year. This suggests a possible upside of 69.5% from the stock's current price.
View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts.

Travere Therapeutics' stock was trading at $21.03 on January 1st, 2023. Since then, TVTX shares have decreased by 13.5% and is now trading at $18.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our TVTX earnings forecast.

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its quarterly earnings results on Thursday, October, 28th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.13. The firm had revenue of $68.20 million for the quarter, compared to analysts' expectations of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 236.09% and a negative net margin of 130.98%. The company's revenue was up 33.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.44) earnings per share.

ETFs with the largest weight of Travere Therapeutics (NASDAQ:TVTX) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and iShares Biotechnology ETF (IBB).

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Travere Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.58%), State Street Corp (5.85%), Macquarie Group Ltd. (4.88%), Renaissance Technologies LLC (2.87%), Assenagon Asset Management S.A. (2.23%) and Pictet Asset Management SA (2.08%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends.

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TVTX stock can currently be purchased for approximately $18.20.

Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $1.36 billion and generates $212.02 million in revenue each year. The company earns $-278,480,000.00 in net income (profit) each year or ($4.44) on an earnings per share basis.

The company employs 310 workers across the globe.

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280.